Research statistics
Dulaglutide research: publications and trials
At a glance
Publications, all years
1,082
Since 2010
Publications in 2026 so far
181
Through November 15, 2026
Human clinical research
53.6%
577 of 1,077 classified
Registered clinical trials
121
ClinicalTrials.gov
Randomized controlled trials
171
Publications reporting an RCT in people
Systematic reviews and meta-analyses
133
Preclinical studies
12.4%
76 animal · 16 in vitro · 42 computational
Records that only mention it
204
Not counted above
Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 5 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Dulaglutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2010 | 0 | 1 | 1 | 0 | 2 |
| 2011 | 3 | 0 | 1 | 0 | 4 |
| 2012 | 4 | 0 | 0 | 0 | 4 |
| 2013 | 0 | 0 | 3 | 0 | 3 |
| 2014 | 7 | 0 | 6 | 4 | 17 |
| 2015 | 12 | 3 | 22 | 4 | 41 |
| 2016 | 16 | 1 | 24 | 2 | 43 |
| 2017 | 17 | 4 | 18 | 1 | 40 |
| 2018 | 30 | 6 | 21 | 7 | 64 |
| 2019 | 36 | 16 | 10 | 6 | 68 |
| 2020 | 45 | 12 | 25 | 7 | 89 |
| 2021 | 43 | 9 | 18 | 4 | 74 |
| 2022 | 39 | 14 | 13 | 6 | 72 |
| 2023 | 62 | 13 | 16 | 1 | 92 |
| 2024 | 73 | 19 | 26 | 9 | 127 |
| 2025 | 88 | 19 | 41 | 13 | 161 |
| 2026 (to date) | 102 | 17 | 52 | 10 | 181 |
Study types
| Observational human study | 297 |
|---|---|
| Randomized controlled trial | 171 |
| Review | 164 |
| Meta-analysis | 81 |
| Animal study | 76 |
| Editorial, letter or other | 69 |
| Case report | 64 |
| Systematic review | 52 |
| Other clinical trial | 45 |
| Computational study | 42 |
| In vitro study | 16 |
| Not yet classified | 5 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 985 |
|---|---|
| Endocrinology | 715 |
| Obesity and weight management | 228 |
| Cardiovascular | 191 |
| Gastrointestinal | 105 |
| Neurological and mental health | 104 |
| Reproductive and sexual health | 53 |
| Immune system | 40 |
| Musculoskeletal | 22 |
| Cognitive health | 21 |
| Oncology | 21 |
| Dermatology | 15 |
Registered clinical trials
12 of 85 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 95 · Recruiting: 8 · Unknown status: 8 · Active, not recruiting: 3 · Not yet recruiting: 3 · Terminated: 3 · Enrolling by invitation: 1
Phase not applicable: 16 · Phase 1: 22 · Phase 1 / Phase 2: 2 · Phase 2: 23 · Phase 2 / Phase 3: 2 · Phase 3: 34 · Phase 4: 22
The 50 most recently started of 121 trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Glucagon-like peptide-1 receptor agonists and risk of arrhythmias: A network meta-analysis.
Heart rhythm · October 26, 2026 · Meta-analysis · cited 0 times
PMID 42933519 · DOI 10.1016/j.hrthm.2026.10.052 · Reviews and meta-analyses
- Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
World journal of methodology · September 20, 2026 · Meta-analysis · cited 0 times · open access
PMID 42626264 · DOI 10.5662/wjm.119385 · Reviews and meta-analyses
- GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.
Drugs · September 12, 2026 · Meta-analysis · cited 1 times · open access
PMID 42730869 · DOI 10.1007/s40265-026-02365-3 · Reviews and meta-analyses
- Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.
Frontiers in endocrinology · September 11, 2026 · Meta-analysis · cited 0 times · open access
PMID 42798476 · DOI 10.3389/fendo.2026.1934027 · Reviews and meta-analyses
- Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.
PeerJ · September 8, 2026 · Meta-analysis · cited 0 times · open access
PMID 42729958 · DOI 10.7717/peerj.21713 · Reviews and meta-analyses
- Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · August 4, 2026 · Meta-analysis · cited 0 times
PMID 42551699 · DOI 10.1016/j.eprac.2026.07.018 · Reviews and meta-analyses
- Incorporating estimands into meta-analyses of clinical trials.
Research synthesis methods · July 30, 2026 · Meta-analysis · cited 0 times · open access
PMID 42527984 · DOI 10.1017/rsm.2026.10107 · Reviews and meta-analyses
- Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Diabetology & metabolic syndrome · July 24, 2026 · Meta-analysis · cited 0 times · open access
PMID 42897592 · DOI 10.1186/s13098-026-02248-3 · Reviews and meta-analyses
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
JAMA internal medicine · May 1, 2026 · Meta-analysis · cited 23 times · open access
PMID 41770554 · DOI 10.1001/jamainternmed.2025.8222 · Reviews and meta-analyses
- Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.
Canadian journal of diabetes · April 10, 2026 · Meta-analysis · cited 0 times
PMID 41967797 · DOI 10.1016/j.jcjd.2026.04.001 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (London, England) · June 9, 2019 · Randomized controlled trial · cited 3,146 times · open access
PMID 31189511 · DOI 10.1016/s0140-6736(19)31149-3 · Human clinical research
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
The lancet. Diabetes & endocrinology · August 14, 2019 · Meta-analysis · cited 1,658 times · open access
PMID 31422062 · DOI 10.1016/s2213-8587(19)30249-9 · Reviews and meta-analyses
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Molecular metabolism · October 14, 2020 · Review · cited 1,624 times · open access
PMID 33068776 · DOI 10.1016/j.molmet.2020.101102 · Reviews and meta-analyses
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet (London, England) · October 4, 2018 · Randomized controlled trial · cited 815 times
PMID 30293770 · DOI 10.1016/s0140-6736(18)32260-8 · Human clinical research
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
The lancet. Diabetes & endocrinology · February 1, 2018 · Randomized controlled trial · cited 788 times
PMID 29397376 · DOI 10.1016/s2213-8587(18)30024-x · Human clinical research
Latest publications
- Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial.
Diabetes, obesity & metabolism · November 9, 2026 · Observational human study · cited 0 times · open access
PMID 43003406 · DOI 10.1111/dom.71515 · Human clinical research
- GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study.
Balkan medical journal · November 2, 2026 · Observational human study · cited 0 times · open access
PMID 42969666 · DOI 10.4274/balkanmedj.galenos.2026.2026-7-49 · Human clinical research
- The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents.
Bone · November 2, 2026 · Review · cited 0 times
PMID 42971377 · DOI 10.1016/j.bone.2026.118160 · Reviews and meta-analyses
- Effects of glucagon-like peptide-1 analogs on prolactin levels: A secondary analysis of a randomized, double-blind, placebo-controlled crossover trial.
Journal of neuroendocrinology · November 1, 2026 · Randomized controlled trial · cited 0 times · open access
PMID 42985994 · DOI 10.1111/jne.70308 · Human clinical research
- Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.
Pharmacoepidemiology and drug safety · November 1, 2026 · Observational human study · cited 0 times · open access
PMID 42946127 · DOI 10.1002/pds.70517 · Human clinical research
- Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.
Alzheimer's & dementia (New York, N. Y.) · October 28, 2026 · Animal study · cited 0 times · open access
PMID 42959452 · DOI 10.1002/trc2.70336 · Animal studies
- GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways.
British journal of pharmacology · October 28, 2026 · Animal study · cited 0 times
PMID 42950887 · DOI 10.1111/bph.70720 · Animal studies
- Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation.
Brain communications · October 27, 2026 · Randomized controlled trial · cited 0 times · open access
PMID 43011533 · DOI 10.1093/braincomms/fcag410 · Human clinical research
- Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.
Diabetes care · October 27, 2026 · Observational human study · cited 0 times
PMID 42937520 · DOI 10.2337/dc26-2069 · Human clinical research
- Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.
Transplantation · October 27, 2026 · Observational human study · cited 0 times
PMID 42934184 · DOI 10.1097/tp.0000000000005945 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Dulaglutide; LY2189265; Trulicity
((TITLE_ABS:"Dulaglutide" OR CHEM:"Dulaglutide") OR (TITLE_ABS:"LY2189265" OR CHEM:"LY2189265" OR TITLE_ABS:"LY 2189265" OR CHEM:"LY 2189265") OR (TITLE_ABS:"Trulicity" OR CHEM:"Trulicity")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Dulaglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/dulaglutide